29.10.2010
- Sanofi-Aventis expanded its consumer health business in China with a $520.6 million takeover, showing it remains in the market for smaller bolt-on deals as it tries to buy U.S...
28.10.2010
- Danish-listed biotech Genmab is vulnerable to a takeover due to its current low share price, and the company needs more time to develop its full potential, its chief executive told...
20.10.2010
- France's Sanofi Aventis said on Wednesday that it had received the green light from U.S. antitrust regulators to take-over the U.S. biotech Genzyme. Sanofi said that the waiting...
18.10.2010
- Sanofi-Aventis' position remains unchanged regarding a $18.5 billion hostile offer for Genzyme, Sanofi Chief Executive Chris Viehbacher told Reuters on the sidelines of the Women's...
14.10.2010
- As Sanofi-Aventis hunkers down for a long battle to buy Genzyme, the specter of a new proxy battle for control of the U.S. biotech will become an increasingly real threat...
08.10.2010
- Genzyme said that Sanofi-Aventis's chief executive had privately opened the door in September to paying as much as $80 per share for the U.S. company before going hostile with a...
07.10.2010
- Sanofi-Aventis finally made a hostile $18.5 billion tender offer for Genzyme, but it acknowledged that Genzyme's willingness, and possibly a higher price, may be needed to succeed...
06.10.2010
- From October 13, 2010, when Sepawa opens, Fulda will become the center of an important and much diversified industry for three days. More than 1000 attendants have registered. Prof...
06.10.2010
- In commercializing bio-based fuels and materials, technology developers and corporations constantly hover between competition and cooperation. Nimble innovators quickly transform...
04.10.2010
- French drugmaker Sanofi-Aventis launched a hostile bid for Genzyme at $69 per share, or $18.5 billion, setting off what could be a protracted battle for control of the U.S. biotech...
